GRM2: Metabotropic glutamate receptor 2
Dimeric G protein-coupled receptor which is activated by the excitatory neurotransmitter L-glutamate.
- Drugs that act on it: 6
- Approved: 0
- In phases 1 to 3: 6
- Sponsors: 4
Who is on it, and how far along
Every drug ChEMBL records acting on GRM2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 5
- Other 1
Approved0
Phase 31
Phase 22
Phase 13
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Denovo Biopharma LLC117%
- Eli Lilly117%
- Johnson & Johnson117%
- Roche117%
| Pomaglumetad methionil anhydrous | Phase 3 | Denovo Biopharma LLC | Small molecule | Agonist | 0 |
| Decoglurant | Phase 2 | Roche | Small molecule | ModulatorMetabotropic glutamate receptor 2 modulator | 0 |
| JNJ-40411813 | Phase 2 | Johnson & Johnson | Small molecule | Positive allosteric modulatorMetabotropic glutamate receptor 2 positive allosteric modulator | 0 |
| LY2969822 | Phase 1 | — | Other | Agonist | 0 |
| LY2979165 | Phase 1 | Eli Lilly | Small molecule | Agonist | 0 |
| LY404039 | Phase 1 | — | Small molecule | Agonist | 0 |
- Schizophrenia0.34
- Neurodegenerative disease0.27
- Crystal arthropathy0.20
- Abnormality of the skeletal system0.19
- Major depressive disorder0.12
- Epilepsy0.09
- Psychiatric disorder0.08
- Anxiety disorder0.07
- Seizure0.07
- Parkinson disease0.07
- Genetic developmental and epileptic encephalopathy0.07
- Anxiety0.07
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5137, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q14416, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets